pm mfvt1
    • Main page
      • About journal
      • Articles. Working with contents
      • Editor-in-chief
      • Editorial Council
      • Editorial Board


      • For authors
      • Standards for formatting information
      • Reviewing
      • Politics editorial board
      • Ethics of journal publications


      • For advertisers
      • Subscription
      • About the Publishing House
      • Contact us
  • Tag › E.V. BOBYKIN

    Anti-angiogenic therapy for treatment of macular disorders in ophthalmology. Literature review

    Редактор | 2018, Practical medicine part 16 №05 (18) Ophthalmology. Otorhinolaryngologypractical | 26 сентября, 2018

    E.V. BOBYKIN Ural State Medical University of the Ministry of Healthcare of the Russian Federation, 3 Repina Str., Yekaterinburg, Russian Federation, 620028   Bobykin E.V. — Cand. Med. Sc., Associate Professor of the Department of Ophthalmology, tel. (343) 214 80 00, e-mail: [email protected]  Abstract. The review presents current literature data on the anti-angiogenic therapy of macular […]

    Tag: 2018, anti-VEGF therapy, E.V. BOBYKIN, fixed mode, Practical medicine part 16 №05 (18) Ophthalmology. Otorhinolaryngologypractical, regimen, “as needed” (PRN), “treat-and-extend” (T&E)
    Комментарии к записи Anti-angiogenic therapy for treatment of macular disorders in ophthalmology. Literature review отключены

    Results of a 12-month follow-up of neovascular age-related macular degeneration after switching an angiogenesis inhibitor in real clinical practice

    Редактор | 2018, Practical medicine 03 (18) Ophthalmology | 10 апреля, 2018

    E.V. BOBYKIN, S.A. KOROTKIKH, R.V. BUSLAEV Ural State Medical University, 3 Repin St., Ekaterinburg, Russian Federation, 620028   Bobykin E.V. ― Cand. Med. Sc., Assistant Professor, Assistant Professor of the Ophthalmology Department, tel. (343) 214-80-00, e-mail: [email protected] Korotkikh S.A. ― D. Med. Sc., Professor, Head of the Ophthalmology Department, tel. (343) 214-86-67, e-mail: [email protected] Buslaev R.V. […]

    Tag: 2018, aflibercept switching, E.V. BOBYKIN, neovascular («wet») age-related macular degeneration, Practical medicine 03 (18) Ophthalmology, R.V. BUSLAEV, ranibizumab, S.A. KOROTKIKH, switch back
    Комментарии к записи Results of a 12-month follow-up of neovascular age-related macular degeneration after switching an angiogenesis inhibitor in real clinical practice отключены

    Duration of anti-VEGF therapy of neovascular macular diseases in real clinical practice

    Редактор | 2017, Practical medicine 09 (17) Ophthalmology. Part 2 | 6 сентября, 2017

    E.V. BOBYKIN, O.V. MOROZOVA, R.V. BUSLAEV Ural State Medical University, 3 Repina Str., Yekaterinburg, Russian Federation, 620028  Bobykin E.V. — Cand. Med. Sc., Associate Professor of the Ophthalmology Department, tel. (343) 214-80-00, e-mail: [email protected] Morozova O.V. — ophthalmologist, applicant of the Ophthalmology Department, tel. (343) 214-80-00, e-mail: [email protected] Buslaev R.V. — clinical resident of the […]

    Tag: 2017, anti-VEGF therapy, duration of treatment, E.V. BOBYKIN, neovascularization, O.V. MOROZOVA, Practical medicine 09 (17) Ophthalmology. Part 2, R.V. BUSLAEV, ranibizumab, real clinical practice
    Комментарии к записи Duration of anti-VEGF therapy of neovascular macular diseases in real clinical practice отключены

    Immediate results of switching the anti-VEGF agent in the treatment of neovascular age-related macular degeneration in clinical practice

    Редактор | 2017, Original articles, Practical medicine 03 (17) Ophthalmology | 27 апреля, 2017

    E.V. BOBYKIN, S.A. KOROTKIKH Ural State Medical University, 3 Repin Str., Yekaterinburg, Russian Federation, 620028  Bobykin E.V. ― Cand. Med. Sc., Associate Professor of the Department of Ophthalmology, tel. +7-912-240-03-63, e-mail: [email protected] Korotkikh S.A. ― D. Med. Sc., Professor, Head of the Department of Ophthalmology, tel. (343) 214-86-67, e-mail: [email protected] Early results of the switching […]

    Tag: 03, 2017, aflibercept, E.V. BOBYKIN, neovascular («wet») age-related macular degeneration, ranibizumab, S.A. KOROTKIKH, switching
    Комментарии к записи Immediate results of switching the anti-VEGF agent in the treatment of neovascular age-related macular degeneration in clinical practice отключены
    • rus Версия на русском языке


      usa English version site


      Findloupe

      

    • PARTNERS

      пов  logonew
    «Для
    Practical medicine. Scientific and practical reviewed medical journal
    All rights reserved ©